Joint Clinical Trials Office
Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 26, 2024
REBYOTA™ for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study Study Summary
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 29, 2024
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 11, 2024
A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 11, 2024
Evaluation Of Talazoparib, a PARP Inhibitor, In Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 11, 2024
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 15, 2024
A Phase 3 Trial Investigating Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 15, 2024
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the EndoBarrier® System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 29, 2024
A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination with Abiraterone in Patients with Metastatic Prostate Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 2, 2024
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 2, 2024